About EyeBio
EyeBio is a Healthcare company based in London (United Kingdom) founded in 2021 by Anthony Adamis, and was acquired by Merck Sharp & Dohme in May 2024. Therapies for ophthalmological diseases are developed to restore vision. EyeBio has raised $130 million across 2 funding rounds from investors including Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds. Its chief executive, as recorded, is David Guyer. EyeBio offers products and services including Medicines and Vaccines. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is EYEBIOTECH LIMITED.
Company details
EyeBio was founded in 2021 and is headquartered in London, United Kingdom. Operations center on the biotechnology sector, where therapies for sight-threatening eye diseases are developed. Focus is placed on next-generation treatments to improve vision, including an anti-vascular endothelial growth factor drug targeted at age-related macular degeneration. Research and development activities are conducted to address unmet needs in ophthalmology.
- Headquarters London, United Kingdom
- Founders Anthony Adamis
- Stage Acquired
- SectorsHealthcare
- Website eyebiotech.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Merck Sharp & Dohme (May 2024)
- Legal Name Eyebiotech Limited
- Date of Incorporation 09 Jul, 2021
- Jurisdiction LONDON, UNITED KINGDOM
- Net Profit$20.88 K (USD)as on Dec 31, 2022
- EBITDA$25.52 K (USD)as on Dec 31, 2022
- Total Equity Funding$130M (USD)
in 2 rounds
- Latest Funding Round$65M (USD), Series A
Nov 2023
- InvestorsMerck Sharp & Dohme
& 7 more
- Acquired byMerck Sharp & Dohme
(May 2024)
Products & Services of EyeBio
EyeBio offers a comprehensive portfolio of products and services, including Medicines and Vaccines.
Treatments for diseases like diabetes and oncology
Preventive solutions for infectious diseases
Funding Insights of EyeBio
EyeBio has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130M
- Total Rounds 2
- Last Round Series A — $65M
- First Round $65M
(Feb 2022)
- Investors Count 7
All 2 funding rounds of EyeBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $65M | Series A | – | Bain Capital Life Sciences, Omega Funds | |
| Feb 2022 | $65M | Series A | – | Jeito, SV Health Investors |
8 investors in total: 8 institutional.
Investors in EyeBio
EyeBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
| vertexventureshc.com | ||||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Jeito Capital is focused on financing medical innovation globally. | jeito.life | Paris, France | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Seed and early-stage therapeutics companies are invested in by MRLV. | mrlv.com | Cambridge, United States | ||
Therapies for HIV, cancer, diabetes, and infectious diseases are developed. | 1890 | msd.com | Kenilworth, United States |
Investor details for EyeBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EyeBio
30 people are tracked at EyeBio (21 in leadership, 5 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Anthony Adamis | Co-Founder | Leadership |
David Guyer | CEO | Leadership |
Loni Da Silva | Chief Regulatory Officer | Leadership |
Tamiko Comeaux | Director, Regional Monitoring (us) | Leadership |
Jonathon Dines | Vice President Finance | Leadership |
Cheryl Reburiano | Senior Director, Clinical Operations | Leadership |
Loni da Silva MS RAC | Chief Regulatory Officer | Leadership |
Sarah Milsom | Chief Operating Officer | Leadership |
Anthony P. Adamis | Chief Scientific Officer, Co-Founder, Director & Chair of Advisory Board | Leadership |
Joshua Truby | Director Project Management | Leadership |
Beth Fucito | Director, HR Operstions | Leadership |
Laura Fougman | Executive Assistant to Chief Operating Officer | Leadership |
Laura Kupsch | Vice President Quality Assurance | Leadership |
Jonathan Prenner | Chief Medical Officer | Leadership |
Keith Baker | Senior Vice President Clinical Development | Leadership |
Matthew Snowden | Senior Director Program Leader | Leadership |
Bryce Miller | Associate Vice President, Clinical Trial Strategy And Recruitment | Leadership |
Jingbo Liu | Executive Medical Director | Leadership |
Charles Miller | Associate Vice President | Leadership |
Frances Betts | Global Head, Clinical Operations | Leadership |
10 more people are available in the full profile.
Complete people profiles for EyeBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EyeBio
4 dated milestones of EyeBio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded EyeBio is founded.
- Funding First funding round of $65.0M.
- Funding Latest funding round, Series A, of $65.0M.
- Exit Acquired by Merck Sharp & Dohme.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eyebio
Complete news archive for EyeBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeBio
EyeBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
EyeBio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
David Guyer is the CEO of EyeBio, as recorded in our data.
EyeBio is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a Series A of $65M, raised on Feb 2022.
EyeBio was founded in 2021 and is headquartered in London, United Kingdom. Operations center on the biotechnology sector, where therapies for sight-threatening eye diseases are developed. Focus is placed on next-generation treatments to improve vision, including an anti-vascular endothelial growth factor drug targeted at age-related macular degeneration. Research and development activities are conducted to address unmet needs in ophthalmology.
EyeBio offers Medicines and Vaccines.
EyeBio has 8 investors. Key investors include Merck Sharp & Dohme, Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC, and SV Health Investors.
EyeBio operates through Eyebiotech Limited.
Yes. EyeBio was acquired by Merck Sharp & Dohme in May 2024.